3 Respiratory and Chronic Medicines Leader, Over the Counter Drugs Maker and Pharma Intermediates Maker Stocks With a Strong Future Roadmap: Cipla, Marksans Pharma and Acutaas Chemicals
- November 4, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Cipla, Marksans Pharma and Acutaas Chemicals: ROE of 11.3% to 21.5% and FY22 to FY26 revenue CAGR of 7.1% to 27.5%. Prices as of 3 Nov 2026.
Quick Answer
The three respiratory drug, OTC and pharma chemical stocks to watch are Cipla, Marksans Pharma and Acutaas Chemicals. Their return on equity ranges from 11.3% to 21.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 27.5%. Acutaas Chemicals leads on both return on equity at 21.5% and revenue growth at 27.5% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.
Respiratory drug, OTC and pharma chemical stocks offer a focused view of a sector where demand keeps widening. Cipla, Marksans Pharma and Acutaas Chemicals cover a respiratory medicines leader, an over the counter drugs maker and a pharma intermediates maker.
This list covers three respiratory drug, OTC and pharma chemical stocks with complete current figures: Cipla, Marksans Pharma and Acutaas Chemicals. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Respiratory Drug, OTC and Pharma Chemical Stocks?
Respiratory drug, OTC and pharma chemical stocks are listed companies that sell respiratory and chronic medicines in India and overseas, make over-the-counter and prescription formulations for overseas markets, and produce advanced pharma intermediates and battery additives. Their earnings depend on global drug demand, approvals and export orders.
Respiratory Drug, OTC and Pharma Chemical Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Cipla | 1,396.9 | 107,528 | 32.0 | 36.0 | 11.3 | 0.02 |
| Marksans Pharma | 315.3 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
| Acutaas Chemicals | 3,904 | 31,066 | 70.8 | 36.2 | 21.5 | 0.02 |
On valuation, Cipla and Marksans Pharma trade at a P/E below the industry P/E, while Acutaas Chemicals trades above it, which reflects the growth the market already expects. Readers comparing respiratory drug, OTC and pharma chemical stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Respiratory Drug, OTC and Pharma Chemical Stocks Have a Strong Roadmap in India?
Respiratory drug, OTC and pharma chemical stocks have a strong roadmap in India because rising demand for chronic care, growing overseas medicine use and wider pharma outsourcing keep widening the market for these export linked companies.
- Respiratory care. Chronic therapies serve patients in many countries.
- Overseas formulations. Plants supply medicines to several markets.
- Intermediates. Pharma and battery makers need specialty inputs.
Why Cipla Features Among These Respiratory Drug, OTC and Pharma Chemical Stocks
Among the respiratory drug, OTC and pharma chemical stocks on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.
Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%.
In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.
Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What to watch: Follow new product launches in the United States and the growth of key domestic brands.
Why Marksans Pharma Features Among These Respiratory Drug, OTC and Pharma Chemical Stocks
Among the medicine and intermediate shares on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%.
Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Why Acutaas Chemicals Features Among These Respiratory Drug, OTC and Pharma Chemical Stocks
Among the three companies on this list, Acutaas Chemicals, earlier known as Ami Organics, is a Surat-based speciality chemicals company that makes advanced pharmaceutical intermediates, battery electrolyte additives and active ingredients for global customers.
The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2.
Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%.
Roadmap: The company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.
What to watch: Follow capacity additions, new product approvals and export orders.
Cipla vs Marksans Pharma vs Acutaas Chemicals on Key Financials
The table below sets the three respiratory drug, OTC and pharma chemical stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Cipla | 22,044 | 29,045 | 7.1% | 3,870 | 13.3% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
| Acutaas Chemicals | 523 | 1,381 | 27.5% | 356 | 25.8% |
Acutaas Chemicals posts the highest return on equity in this group at 21.5%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Acutaas Chemicals shows the fastest revenue growth with a 27.5% compound annual rate. A useful habit with respiratory drug, OTC and pharma chemical stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Respiratory Drug, OTC and Pharma Chemical Stocks
Every theme carries risks that deserve a check before any decision. For these respiratory drug, OTC and pharma chemical stocks, the main points are: Long-term medicine and intermediate shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter respiratory drug, OTC and pharma chemical stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Respiratory Drug, OTC and Pharma Chemical Stocks
Respiratory drug, OTC and pharma chemical stocks reward patient research into demand, execution and financial strength. Cipla, Marksans Pharma and Acutaas Chemicals each have a clear plan to grow. Based on the 3 November 2026 close, Cipla trades at Rs 1,396.9, Marksans Pharma at Rs 315.3 and Acutaas Chemicals at Rs 3,904.
Download the Univest iOS App or Univest Android App to track respiratory drug, OTC and pharma chemical stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are respiratory drug, OTC and pharma chemical stocks?
Ans. Respiratory drug, OTC and pharma chemical stocks are listed companies that sell respiratory and chronic medicines in India and overseas, make over-the-counter and prescription formulations for overseas markets, and produce advanced pharma intermediates and battery additives. Their earnings depend on global drug demand, approvals and export orders. This list looks at three of them, Cipla, Marksans Pharma and Acutaas Chemicals, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.
Which respiratory drug, OTC and pharma chemical stocks are covered in this list?
Ans. This list covers Cipla, Marksans Pharma and Acutaas Chemicals. Based on the 3 November 2026 close, Cipla traded at Rs 1,396.9, Marksans Pharma at Rs 315.3 and Acutaas Chemicals at Rs 3,904. Their return on equity ranges from 11.3% to 21.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 27.5%.
Why do respiratory drug, OTC and pharma chemical stocks have a strong future roadmap in India?
Ans. Respiratory drug, OTC and pharma chemical stocks have a strong roadmap in India because rising demand for chronic care, growing overseas medicine use and wider pharma outsourcing keep widening the market for these export linked companies. The main drivers are as follows. Respiratory care. Chronic therapies serve patients in many countries. Overseas formulations. Plants supply medicines to several markets. Intermediates. Pharma and battery makers need specialty inputs. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Cipla performed financially?
Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
How has Acutaas Chemicals performed financially?
Ans. Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%. The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2. Looking ahead, the company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.
What risks should investors check before buying respiratory drug, OTC and pharma chemical stocks?
Ans. Investors should check a few risks before buying respiratory drug, OTC and pharma chemical stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of respiratory drug, OTC and pharma chemical stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.